Moderna plans to request clearance for its coronavirus vaccine in the US and Europe on Monday, after a new analysis showed the vaccine was highly effective in preventing Covid-19, with no serious safety problems.
The primary analysis, which included 196 cases, found the vaccine was 94.1% effective, in line with preliminary findings released earlier this month.
None of the participants in the trial who’d received the vaccine developed severe Covid-19. All 30 severe cases observed in the study occurred in participants who received placebo shots, according to a company statement.
The shares extended their gains to as much as 12% before US markets opened, hitting a record of $142.85. They have risen more than six-fold since the year began.
The new results put the Cambridge, Massachusetts-based biotechnology company on track to have one of the first Covid-19 vaccines to be cleared in the US.
A similar vaccine from Pfizer Inc. and BioNTech SE was submitted to U.S. regulators earlier this month and is scheduled to be reviewed ahead of Moderna’s shot.
Moderna said it plans to apply on Monday for an emergency-use authorization for the vaccine in the US and for conditional marketing authorization in Europe.
Advisers to the U.S. Food and Drug Administration will likely scrutinize the data at a public meeting on 17 December, the company said, one week after a similar review of Pfizer’s vaccine is expected to take place.
“We have been working nonstop in the last few weeks” to get the vaccine data ready to submit to regulators, Stephane Bancel, Moderna’s chief executive officer, said in an interview.
Once authorities sign off, the company will move quickly to distribute the shots, part of a vast vaccination effort that will unfold as hospitals in the US strain under a surge in infections.
“We are ready today to ship the vaccine,” Bancel said. “We have millions of doses ready, we have more and more every couple days.”
If the vaccine is cleared in the U.S., which Bancel said could occur as soon as 24 to 72 hours after the 17 December meeting, Moderna’s entire inventory will be sent to the federal government.
New lots will be shipped as soon as they pass muster, Bancel said. The company expects to be able to ship 20 million doses in the U.S. by the end of the year.
The new analysis showed the vaccine worked consistently well in older and younger adults, as well as minorities, the company said.
Moderna didn’t disclose the vaccine’s exact efficacy in those groups, and Bancel said that more detailed data is still being finalized.
Overall, there were 185 cases of Covid-19 in trial participants who got a placebo, and 11 cases in people who got the vaccine.
As mandated by the FDA, Moderna said it had also accumulated two months of safety data from its final-stage trial of more than 30,000 participants.
Reported side effects included injection-site pain, fatigue, muscle or joint pain and headache. The side effects were more common and severe after the second dose of the two-dose vaccine, Moderna said.
The results bolster an interim analysis released on 16 November, which showed the vaccine was 94.5% effective in preventing symptomatic Covid-19 and successful in preventing the most severe infections.
On Nov. 20, Pfizer and German partner BioNTech became the first to seek emergency U.S. clearance for a vaccine, after their shot was 95% effective in preventing symptomatic Covid-19 in the final analysis of a nearly 44,000 participant trial.
That vaccine application will be reviewed by a panel of FDA advisers on 10 December, potentially paving the way for it to become available soon after that.
Both the Moderna and Pfizer vaccines rely on a technology called messenger RNA that turns the body’s cells into vaccine-making factories.
Messenger RNA has never before been used to develop an approved vaccine.
Moderna, which has co-developed the mRNA candidate with the National Institutes of Health, has already reached agreements to supply 100 million doses to the US and 80 million to the European Union, among others.